Cardiff Oncology reports Q1 cash $46.1M, FDA aligns on Phase 3 design for onvansertib

Cardiff Oncology, Inc.

2026-Q1 EPS reported -$0.18 revenue$41,000

Cash and investments $46.1M at Q1 end; net cash used $12.3M, runway into Q1 2027.
Completed End-of-Phase 2 FDA meeting; selected 30 mg onvansertib + FOLFIRI/bev for Phase 3.
Phase 2 CRDF-004: 30 mg arm ORR 72.2% vs SoC 43.2%; PFS HR 0.38 vs FOLFIRI/bev.
Appointed Mani Mohindru as permanent CEO, Josh Muntner as CFO, Ajay Aggarwal as COO.
Updated onvansertib data to be presented at ASCO 2026 rapid oral presentation.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Cardiff Oncology, Inc. reported financial results for first quarter ended March 31, 2026.

Period: first quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 14, 2026, Cardiff Oncology, Inc. issued a press release announcing a business update and financial results for the first quarter ended March 31, 2026.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Cardiff Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0001213037-26-000013

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.